From: Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats
Variables | Sham | Control | Low-dose | High-dose |
---|---|---|---|---|
Pre-medical treatment (8 weeks of model production, n = 5 each group) | ||||
Body weight (g) | 254.8 ± 6.6* | 286.6 ± 7.0 | 290.3 ± 8.7 | 288.5 ± 10.4 |
TG (mmol/L) | 1.15 ± 0.17* | 1.79 ± 0.33 | 1.78 ± 0.32 | 1.76 ± 0.43 |
TC (mmol/L) | 3.96 ± 0.26* | 4.97 ± 0.34 | 4.96 ± 0.37 | 4.95 ± 0.45 |
LDL-C (mmol/L) | 2.12 ± 0.24* | 2.85 ± 0.31 | 2.91 ± 0.57 | 2.89 ± 0.44 |
HDL-C (mmol/L) | 1.07 ± 0.12 | 1.11 ± 0.04 | 1.12 ± 0.04 | 1.10 ± 0.05 |
FBG (mmol/L) | 4.12 ± 0.08* | 4.49 ± 0.11 | 4.51 ± 0.12 | 4.50 ± 0.08 |
NO (umol/L) | 12.67 ± 1.37* | 9.65 ± 1.05 | 9.26 ± 1.08 | 9.44 ± 1.02 |
CRP (mg/L) | 2.15 ± 0.42* | 6.37 ± 0.55 | 6.52 ± 0.73 | 6.46 ± 0.52 |
MDA (nmol/L) | 0.90 ± 0.06* | 2.46 ± 0.18 | 2.57 ± 0.12 | 2.52 ± 0.19 |
ADMA (ng/mL) | 43.37 ± 6.65* | 60.68 ± 10.17 | 62.22 ± 8.17 | 62.30 ± 8.22 |
Post-medical treatment (4 weeks of medical treatment, n = 10 each group) | ||||
Body weight (g) | 277.3 ± 8.2* | 301.2 ± 7.4 | 299.6 ± 10.3 | 300.6 ± 10.5 |
TG (mmol/L) | 1.17 ± 0.22* | 1.83 ± 0.42 | 1.67 ± 0.37 | 1.50 ± 0.29# |
TC (mmol/L) | 3.98 ± 0.33* | 5.00 ± 0.62 | 4.81 ± 0.56 | 4.56 ± 0.36# |
LDL-C (mmol/L) | 2.13 ± 0.23* | 2.87 ± 0.36 | 2.64 ± 0.52 | 2.43 ± 0.35# |
HDL-C (mmol/L) | 1.07 ± 0.14 | 1.10 ± 0.05 | 1.12 ± 0.03 | 1.10 ± 0.03 |
FBG (mmol/L) | 4.14 ± 0.07* | 4.56 ± 0.13 | 4.46 ± 0.15 | 4.41 ± 0.13 |
NO (umol/L) | 12.88 ± 1.56* | 9.03 ± 0.68 | 10.07 ± 0.64 | 10.85 ± 0.57# |
CRP (mg/L) | 2.13 ± 0.39* | 6.43 ± 0.42 | 5.87 ± 0.16 | 5.35 ± 0.66# |
MDA (nmol/L) | 0.93 ± 0.07* | 2.52 ± 0.15 | 2.29 ± 0.09 | 2.05 ± 0.07# |
ADMA (ng/mL) | 44.64 ± 7.08* | 62.33 ± 10.08 | 58.75 ± 8.07 | 54.46 ± 9.15# |
ALT (U/L) | 21.43 ± 3.24 | 26.55 ± 5.21 | 24.47 ± 6.08 | 22.39 ± 3.76 |
AST (U/L) | 24.36 ± 6.77 | 22.55 ± 4.09 | 21.56 ± 3.35 | 23.30 ± 6.12 |
CK (U/L) | 18.24 ± 2.23 | 21.30 ± 2.08 | 20.07 ± 3.35 | 20.35 ± 2.56 |